New Capsule Form of Adrulipase Alfa for EPI May Soon Enter Trial

New Capsule Form of Adrulipase Alfa for EPI May Soon Enter Trial

316197

New Capsule Form of Adrulipase Alfa for EPI May Soon Enter Trial

First Wave BioPharma has filed two new patents related to adrulipase, a yeast-derived enzyme that the company is developing to treat exocrine pancreatic insufficiency in people with cystic fibrosis (CF). One application is related to dosage forms, methods of treatment, and manufacturing methods for the investigational medication. This includes a new capsule formulation, taken with food, that dissolves in the stomach and disperses acid-resistant micro-granules to thoroughly mix with food during the digestion process. First Wave is…

You must be logged in to read/download the full post.